CELLECTIS - ADR
CLLSNASDAQ🏆 #3076 by market capUS Equity
$419.87▲ $11.00 (+2.62%)
Simulated price1h—
24h▲ 2.6%
7d—
14d—
30d—
1y—
🏦Market Cap
$179M
Small Cap
📈Revenue Growth (YoY)
+56.8%
High Growth
📊Gross Margin
34.8%
Moderate
💵FCF Margin
39.5%
Strong
⚖️P/S Ratio
1.6x
Cheap
Otter Score
58
Weak
No chart data available for CLLS.
Trading Snapshot
- Day Range
- $418.18 – $424.48
- 52-Week Range
- $2.03 – $4.84
- Volume
- $3.43B
- Avg Volume
- $4.48B
- Shares Outstanding
- 72.1M
- Next Earnings
- Sep 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $111M
- Last Q Revenue
- $30M
- P/E Ratio
- —
- P/S Ratio
- 1.6x
- EPS (TTM)
- $-0.85
- Dividend Yield
- —
Why Investors Own CLLS
- ✓High-growth profile — revenue up -0.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 44% gross margin and 14% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$111M▲ +0.5% YoY
Gross Margin (TTM)
44.2%▲ +0.8% YoY
Operating Income (TTM)
$38M▲ +0.5% YoY
Free Cash Flow (TTM)
$15M▲ +0.5% YoY
About CELLECTIS - ADR
A company profile for CELLECTIS - ADR isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
58/100
Analyst Price Target
ⓘAverage Target
$436.09
▲ +3.9% Upside
High Target$474.44
Low Target$405.44
Based on 25 analysts
Latest News & Updates
🚀
CNBC·2h ago
CELLECTIS - ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift CLLS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
CELLECTIS - ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.